About This Fund
Forbion Ventures Fund VII is an early-stage life sciences venture capital fund managed by Forbion, the leading European biopharma-focused investment firm headquartered in Naarden, Netherlands, with offices in Munich and Boston. Closing in October 2024 at €890 million — making it one of the largest European life sciences VC funds of its vintage — Fund VII is the seventh iteration of Forbion's flagship ventures strategy, which has been operating since the firm's spinout from ABN AMRO Capital Life Sciences in 2006. Forbion manages approximately €5 billion in assets across eleven funds.
Forbion Ventures Fund VII targets early-stage and emerging biotech companies, investing from pre-clinical through early clinical development stages (Seed, Series A and Series B), including the creation of NewCos built around validated drug targets from pharmaceutical companies and experienced management teams. The fund applies Forbion's differentiated company-building approach to address high unmet medical needs across oncology, central nervous system disorders, immunology and inflammation, cardiovascular and metabolic diseases, ophthalmology, respiratory diseases, rare and genetic disorders, and nephrology. The expected portfolio comprises approximately 15 biotech companies across Europe and North America.
The fund was raised from a strong institutional LP base, including MN, the Dutch pension asset management firm that committed €210 million combined across Fund VII and Forbion's Growth Opportunities Fund III on behalf of the Dutch pension funds PMT, PME, and MITT. The European Investment Fund has been a historical Forbion LP. With more than two decades of biopharma-focused investment, Forbion brings sector-specific scientific diligence, deep industry relationships, and a consistent track record in creating and scaling therapeutics companies from inception through late-stage development and public markets.